EGFR and large cell neuroendocrine carcinoma: Considering that our patient did not receive TKI therapy until recurrence, it is likely that LCNEC component existed before cytotoxic chemotherapy and the tumor did not transform from adenocarcinoma to LCNEC, and recurrent sites were inferred to include the LCNEC component which showed response to EGFR-TKI.